肝硬化逆转的临床评价

赵文姗; 谢雯

doi:10.3969/j.issn.1001-5256.2019.04.005

肝硬化逆转的临床评价

DOI: 10.3969/j.issn.1001-5256.2019.04.005

赵文姗,
谢雯

首都医科大学附属北京地坛医院肝病中心

基金项目:

北京市科委科技计划重大项目(D171100003117005)；北京市医院管理局消化内科学科协同发展中心消化专项重点项目(XXZ0402)；北京市医院管理局重点医学专业发展计划(ZYLX201808)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1766
- HTML全文浏览量: 13
- PDF下载量: 497
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-12
- 出版日期: 2019-04-20

Clinical assessment of the reversal of liver cirrhosis: “Point of return”

Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University

Research funding:

摘要

摘要: 目前大量临床研究已经证实,部分肝硬化可以实现逆转。因此,可准确评估肝硬化能否逆转以及何时逆转的方法成为临床研究焦点。这有助于更具有特异性地评估治疗效果,调整治疗方案以及判断预后结局等。从无创模型以及肝活组织检查等多方面,来探讨不同病因肝硬化逆转后各项指标的应用,旨在寻求更精准地反映逆转特征及手段。
- 肝硬化 /
- 生物学标记 /
- 病理学,临床
Abstract: Nowadays, many clinical studies have demonstrated that some patients can achieve the reversal of liver cirrhosis. Therefore, the methods for accurate assessment of whether the reversal of liver cirrhosis can be achieved and when it is achieved have become the hotspots in clinical research. This helps with the specific evaluation of therapeutic outcome, the adjustment of treatment regimen, and the prediction of prognosis. This article introduces the application of various indices after the reversal of liver cirrhosis due to different etiologies from the aspects of noninvasive models and liver biopsy, in order to search for the methods that can accurately reflect the features of reversal.
- liver cirrhosis /
- biological markers /
- pathology, clinical

HTML全文

参考文献(35)

[1]WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38 (2) :518-526.

[2]VALLET-PICHARD A, MALLET V, NALPAS B, et al. FIB-4:An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest[J]. Hepatology, 2007, 46 (1) :32-36.

[3]HUI AY, CHAN HL, WONG VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model[J]. Am J Gastroenterol, 2005, 100 (3) :616-623.

[4]ZENG MD, LU LG, MAO YM, et al. Prediction of significant fibrosis in HBe Ag-positive patients with chronic hepatitis B by a noninvasive model[J]. Hepatology, 2005, 42 (6) :1437-1445.

[5]CASTERA L. Non-invasive tests for liver fibrosis progression and regression[J]. J Hepatol, 2016, 64 (1) :232-233.

[6]SHIFFMAN ML, STERLING RK, CONTOS M, et al. Long term changes in liver histology following treatment of chronic hepatitis C virus[J]. Ann Hepatol, 2014, 13 (4) :340-349.

[7]VILAR-GOMEZ E, CALZADILLA-BERTOT L, FRIEDMAN SL, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH[J]. Liver Int, 2017, 37 (12) :1887-1896.

[8]POYNARD T, MCHUTCHISON J, MANNS M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin[J]. Hepatology, 2003, 38 (2) :481-492.

[9]POYNARD T, MOUSSALLI J, MUNTEANU M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol, 2013, 59 (4) :675-683.

[10]DONG XQ, WU Z, ZHAO H, et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients[J]. J Viral Hepat, 2018.[Epub ahead of print]

[11]KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64 (4) :773-780.

[12]D'AMBROSIO R, AGHEMO A, RUMI MG, et al. A morphometric and immune-histochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J]. Hepatology, 2012, 56:532-543.

[13]EL-RAZIKY M, KHAIRY M, FOUAD A, et al. Effect of direct-acting agents on fibrosis regression in chronic hepatitis C virus patients'treatment compared with interferon-containing regimens[J]. J Interferon Cytokine Res, 2018, 38 (3) :129-136.

[14]DOLMAZASHVILI E, ABUTIDZE A, CHKHARTISHVILI N, et al. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia:Results of hepatology clinic HEPA experience[J]. Eur J Gastroenterol Hepatol, 2017, 29 (11) :1223-1230.

[15]BRUNO S, CROSIGNANI A, FACCIOTTO C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus–induced cirrhosis. A 12-year prospective follow-up study[J]. Hepatology, 2010, 51 (6) :2069-2076.

[16]TANWAR S, TREMBLING PM, HOGAN BJ, et al. Noninvasive markers of liver fibrosis:On-treatment changes of serum markers predict the outcome of antifibrotic therapy[J]. Eur J Gastroenterol Hepatol, 2017, 29 (3) :289-296.

[17]KARSDAL MA, HJULER ST, LUO Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile[J]. Am J Physiol Gastrointest Liver Physiol, 2018.[Epub ahead of print]

[18]LEEMING DJ, VEIDAL SS, KARSDAL MA, et al. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis[J]. Scand J Gastroenterol, 2015, 50 (5) :584-592.

[19]MARCELLIN P, ZIOL M, BEDOSSA P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B[J]. Liver Int, 2009, 29 (2) :242-247.

[20]LI Y, HUANG YS, WANG ZZ, et al. Systematic review with meta-analysis:The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2016, 43 (4) :458-469.

[21]CHON YE, PARK JY, MYOUNG SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis[J]. Am J Gastroenterol, 2017, 112 (6) :882-891.

[22]OMAR H, SAID M, ELETREBY R, et al. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods[J]. Clin Transplant, 2018, 32 (8) :e13334.

[23]LIANG X, XIE Q, TAN D, et al. Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy:A 2-year prospective study[J]. J Viral Hepat, 2018, 25 (3) :296-305.

[24]KIM BS, SEO YS, KIM YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33 (2) :503-510.

[25]MAURO E, CRESPO G, MONTIRONI C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C[J]. Hepatology, 2018, 67 (5) :1683-1694.

[26]LENS S, ALVARADO-TAPIAS E, MARIO Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis[J]. Gastroenterology, 2017, 153 (5) :1273-1283.

[27]D'AMBROSIO R, AGHEMO A, FRAQUELLI M, et al. The diagnostic accuracy of FibroScan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response[J]. J Hepatol, 2013, 59 (2) :251-256.

[28]WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.

[29]BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J]. Liver Int, 2015, 35 (Suppl 1) :78-81.

[30]HYTIROGLOU P, THEISE ND. Regression of human cirrhosis:An update, 18 years after the pioneering article by Wanless et al[J]. Virchows Arch, 2018, 473 (1) :15-22.

[31]LIU SB, IKENAGA N, PENG ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice[J].FASEB J, 2016, 30 (4) :1599-1609.

[32]IKENAGA N, PENG ZW, VAID KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J]. Gut, 2017, 66 (9) :1697-1708.

[33]ZHAO W, YANG A, CHEN W, et al. Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt A) :1129-1137.

[34]SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.

[35]WANG B, SUN Y, ZHOU J, et al. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients[J]. Mod Pathol, 2018, 31 (10) :1567-1577.

施引文献

资源附件(0)

访问统计